Man@pSiNPs-erastin (mannose-modified porous silicon nanoparticles loaded with erastin), targeting TAM to induce ferroptosis, combined with anti-PD-1 to inhibit liver cancer[168]; Cu2WS4-PEG nanozyme induces ferroptosis through the Kelch-like ECH associated protein 1 (KEAP1)/nuclear factor erythroid 2–related factor 2 (NRF2)/heme oxygenase 1 (HMOX1)/glutathione peroxidase 4 (GPX4) pathway, and enhances immunoradiotherapy in combination with radiotherapy and anti-PD-L1[169]. The gene discussed is GPX4; the disease is liver cancer.